Skip to main content
Equibles
WGS logo

WGS · GeneDx Holdings Corp. · Documents

Track WGS — free

Use WGS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research WGS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$52.37 +0.50 (+0.96%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.57B
Shares
29.97M
Volume · Nov 13 1.12M Avg daily vol (3M) 804.77K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $427.54M up 40.0% 10-K filed Feb 23, 2026 Quarterly report New FY2026 Q3 Revenue $123.1M up 5.4% 10-Q filed Nov 9, 2026 Latest results New Revenue rose 5% as adjusted net income reached $8.6 million 8-K filed Nov 9, 2026 Earnings call New Q3 2026 earnings call Held Nov 9, 2026
2026
Nov 9
Earnings call
Revenue rises as profit outlook lifted

GeneDx reported third-quarter 2026 revenue of $123.1 million and adjusted net income of $8.6 million, raised full-year adjusted net income guidance to at least $12 million and reaffirmed revenue guidance of $475 million to $490 million.

3 source passages
Welcome to the GeneDx third quarter 2026 earnings conference call at this time. In the third quarter, we reported $123.1 million in total revenue, expanded adjusted gross margin to 72%, generated adjusted net income of $8.6 million, and resulted over 32,100 exome and genome tests. As we prioritize profitable growth, we're raising full-year adjusted gross margin guidance to approximately 71% and adjusted net income guidance to at least $12 million, and reaffirming full-year revenue guidance of $475 million to $490 million. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 11%, but nine-month net loss reached $93.4 million

GeneDx Holdings Corp. reported nine-month 2026 revenue of $339.8 million, up 11%, but a $93.4 million net loss and $72.0 million operating cash outflow.

Revenue $123.1M ▲ 5.4% Net loss $12.33M Diluted EPS -$0.41
Read from the MD&A section
2 source passages
Total revenue increased by $33.2 million, or 11%, to $339.8 million for the nine months ended September 30, 2026, from $306.6 million for the nine months ended September 30, 2025. Net cash used in operating activities during the nine months ended September 30, 2026 was $72.0 million, driven by a net loss of $93.4 million, net adjustments of $81.7 million and a change in operating assets and liabilities of $60.4 million. Open the document at this passage
Nov 9
Current report 8-K
Revenue rose 5% as adjusted net income reached $8.6 million

GeneDx Holdings Corp. reported revenue of $123.1 million for the quarter ended September 30, 2026, up 5% year-over-year, and adjusted net income of $8.6 million, while maintaining full-year 2026 revenue guidance of $475 to $490 million.

Financial results
4 source passages
On November 9, 2026, GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended September 30, 2026. Revenue grew to $123.1 million, an increase of 5% year-over-year. Adjusted net income was $8.6 million, up $8.2 million from the second quarter of 2026 and compared to adjusted net income of $16.1 million in the third quarter of 2025. Reiterating full year 2026 revenue guidance of $475 to $490 million Open the document at this passage
Aug 3
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $114.44M ▲ 11.4% Net loss $17.74M Diluted EPS -$0.60
May 4
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $102.25M ▲ 17.4% Net loss $63.32M Diluted EPS -$2.16
Feb 23
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $427.54M ▲ 40.0% Net loss $21.02M Diluted EPS -$0.73
2025
Feb 20
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $305.45M ▲ 50.8% Net loss $52.29M Diluted EPS -$1.94
2024
Showing 1–50 of 161 documents
Key facts CIK 1818331 CUSIP 81663L200 13F (30d) 171 filings 144 filers Visit website Investor relations